Specification Sheet

Innovative Bioanalysis LLC. WAC LIGHTING UVF7IN-120V-R1-MOD AEROSOL Page 5 of 11
EXPERIMENTAL SUMMARY:
● Prior to the initial control test and following each trial run the testing area was decontaminated
and prepped per internal procedures.
● Temperature during all test runs was approximately 72F +/- 2F with a relative humidity of 48%.
● Relative humidity and temperature were taken in two sections of the chamber during all tests to
confirm there was no more than a 3% deviation from each side.
● Air samplers were calibrated by the manufacturer on September 3, 2020 and set at a standard
flow of 5.02L/min. Calibration records indicate a 0.20% tolerance.
● All sample collection volumes were set to 10-minute draws per time point.
● Sampling time points were T-20, T-30, T-40, measured in minutes from completed nebulization.
● Low volume mixing fans were turned on prior to nebulization to confirm homogenous
concentrations in the test chamber. Once the overhead fan system was turned on the low
volume mixing fans were turned off.
● Mixing fans were positioned at a 45-degree angle to encourage bioaerosol suspension prior to
starting the UV-C fan system.
● Nebulization for control and viral test challenges were performed in the same manner with the
variable being the UV-C fan unit.
● After nebulization was completed the UV-C fan system was engaged at the highest speed setting
of 6. UV-C light ring was visually confirmed to be operational during testing.
● After each time point collection was completed the chamber was decontaminated and the air
evacuated.
● Sample cassettes were manually removed from the collection system and stored after each time
point and replaced with new cassettes.
● Upon cassette removal at each time point, cassette sets were taken to an adjacent bio safety
cabinet and pooled.
● 1 control was completed, and 3 viral challenges were completed. Each time point was its own
viral challenge, and the chamber was prepped and decontaminated the same way each time.
BIOAEROSOL GENERATION:
For the control and the viral challenges, the nebulizer was filled with the same amount of viral
stock 6.23 x 10^6 TCID50 per mL in FBS based viral media. Solution was nebulized at a flow rate of
1ml/min. Nebulizer was driven by untreated local atmospheric air. The nebulizer’s remaining viral stock
volume was weighed after each completion to confirm the same amount of viral stock that was
nebulized. Nebulizer was calibrated prior to testing and a particle counter confirmed average size
disbursement to be .8 microns.
DocuSign Envelope ID: 982FD62D-1207-49F1-B8E3-47E934754AA7